Tuberactinomycin A
Tuberactinomycin A is a basic cyclic peptide antibiotic and a group I intron RNA splicing inhibitor, with an IC50 of 10 μM against the G-binding site of bacteriophage T4 group I intron RNA. Tuberactinomycin A exerts antibacterial effects by acting on the initiation and elongation steps of bacterial bacteria ribosomes to inhibit prokaryotic protein synthesis. Tuberactinomycin A competes with guanosine cofactors for binding to the G-binding site of group I intron RNA, forms electrostatic interactions with the RNA backbone, and inhibits the self-splicing of bacteriophage T4 td and sunY group I introns, and its inhibitory activity depends on Mg2+ concentration. Tuberactinomycin A can be used in studies related to bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 33103-21-8
- Formula: C25H43N13O11
- Molecular Weight:701.70
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Antibiotic Isoforms
More
Biological Activity
Description
In Vitro
Tuberactinomycin A (10 μM) potently inhibits self-splicing of the phage T4 td intron and sunY intron with 50% inhibition at 10 μM, making it far more active than earlier identified competitive splicing inhibitors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 33103-21-8
-
Molecular Weight 701.70
-
Formula C25H43N13O11
-
SMILES
O=C(N)NC=C1NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CC(N)C(O)CCN)CNC(=O)C(NC1=O)C2NC(=NC(O)C2)N)CO)CO
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)